EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long‐Term Observed Risk of Clinically Significant Prostate Cancer After Negative mpMRI and Systematic Biopsy in Biopsy‐Naïve Men: A MULTIPROS Subanalysis

Wafa D Aloufi iD, Xinyu Zhang, Magdalena Szewczyk-Bieda iD, Ghulam Nabi, Cheng Wei iD, Luigi Manfredi iD

Prostate Cancer · 2026-01 · 2026 (1)

DOI: 10.1155/proc/9470087 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Prostate Cancer, online erschienen am 20.08.2026. Verfasst von Wafa D Aloufi und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Dundee School of Medicine, Dundee, UK. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taif University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background mpMRI is now widely used before prostate biopsy and has improved the detection of clinically significant prostate cancer (csPCa). However, the subsequent risk of csPCa among men with both negative mpMRI and negative systematic biopsy (SBx) remains uncertain.

Purpose

To evaluate the observed medium‐term risk of csPCa in biopsy‐naïve men with initially negative mpMRI and negative SBx.

Methods

This post hoc longitudinal follow‐up subanalysis included biopsy‐naïve men from the prospective multicenter MULTIPROS trial who had negative baseline mpMRI (PI‐RADS ≤ 2) and negative SBx. Of the 582 enrolled men, 169 had negative mpMRI; 138 underwent baseline SBx, of whom 8 had csPCa, and 31 had < 12 months of follow‐up, leaving 99 men for analysis. Follow‐up was PSA‐based, with repeat mpMRI and biopsy performed when clinically indicated. Kaplan–Meier analysis estimated csPCa‐free survival.

Results

During a mean follow‐up of 61.8 ± 22.1 months, four patients were diagnosed with csPCa (4/99; 4.0%). The mean time from initial negative mpMRI to csPCa diagnosis was 68.3 ± 22.4 months. Repeat biopsy was performed in 16 patients. csPCa‐free survival was 100% at 24 months and 97.3% at 60 months (95% CI: 93.7%–100%).

Conclusion

In this selected cohort of biopsy‐naïve men with both negative mpMRI and negative SBx, the observed incidence of csPCa during medium‐term follow‐up was low but based on only four events. Because repeat imaging and biopsy were selectively triggered rather than systematically performed, the true incidence of csPCa may be underestimated. Continued PSA‐based monitoring, with repeat mpMRI and biopsy when clinically indicated, remains important.

Schlagwörter

Stichwörter der Autor:innen

TRUSactive surveillancebiopsydetection of cancermagnetic resonance imagingprostate-specific antigenprostatic neoplasms

Autor:innen und Institutionen

  • University of Dundee School of Medicine, Dundee, UK.
  • Taif University, Taif, Makkah Province, Saudi Arabia, tu.edu.sa.
  • Division of Population Health and Genomics, University of Dundee, Dundee, UK, dundee.ac.uk.
  • Ninewells Hospital and Medical School, Dundee, UK, dundee.ac.uk.

ORCID-Profile: Wafa D Aloufi, Magdalena Szewczyk-Bieda, Cheng Wei, Luigi Manfredi

Förderung

  • Taif University

Zitieren

APA

Aloufi, W. D., Zhang, X., Szewczyk-Bieda, M., Nabi, G., Wei, C., & Manfredi, L. (2026). Long‐Term Observed Risk of Clinically Significant Prostate Cancer After Negative mpMRI and Systematic Biopsy in Biopsy‐Naïve Men: A MULTIPROS Subanalysis. Prostate Cancer, 2026(1). https://doi.org/10.1155/proc/9470087

Vancouver

Aloufi WD, Zhang X, Szewczyk-Bieda M, Nabi G, Wei C, Manfredi L. Long‐Term Observed Risk of Clinically Significant Prostate Cancer After Negative mpMRI and Systematic Biopsy in Biopsy‐Naïve Men: A MULTIPROS Subanalysis. Prostate Cancer. 2026;2026(1). doi:10.1155/proc/9470087

BibTeX
@article{Aloufi2026,
  author = {Aloufi, Wafa D and Zhang, Xinyu and Szewczyk-Bieda, Magdalena and Nabi, Ghulam and Wei, Cheng and Manfredi, Luigi},
  title = {Long‐Term Observed Risk of Clinically Significant Prostate Cancer After Negative mpMRI and Systematic Biopsy in Biopsy‐Naïve Men: A MULTIPROS Subanalysis},
  journal = {Prostate Cancer},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/proc/9470087}
}
Kostenlos starten →